Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edratide - XTL Biopharmaceuticals

Next Previous
Drug Profile

Edratide - XTL Biopharmaceuticals

Alternative Names: hCDR1; TV-4710

Latest Information Update: 22 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Teva Pharmaceutical Industries; XTL Biopharmaceuticals
  • Class Peptides
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • No development reported Sjogren's syndrome

Most Recent Events

  • 31 Dec 2022 Edratide - XTL Biopharmaceuticals is available for licensing as of 31 Dec 2022. https://www.sec.gov/ix?doc=/Archives/edgar/data/1023549/000121390023021869/f20f2022_xtlbiopharma.htm
  • 31 Dec 2022 XTL Biopharmaceuticals has patent protection for Edratide in the US, Switzerland, Germany, Denmark, Spain, Finland, France, Great Britain, Ireland, Italy, Netherlands and Sweden, China, India, Israel, Japan, Mexico, and Canada prior to December 2022
  • 31 Dec 2022 XTL Biopharmaceuticals has patent protection for Edratide in US, Austria, Denmark, Finland, France, Germany, Ireland, Italy, Liechtenstein, Spain, Sweden, Switzerland, the Netherlands, the UK, Australia, Canada, Hong Kong, India, Israel, Japan, Korea, Mexico, Norway, Hungary and Russia prior to December 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top